Hospital

Specifically, 3 new drugs for sickle cell disease are providing options for patients who are not responding to hydroxyurea.

Spherix Global Insights estimates that SER-109 (Seres Therapeutics; Aimmune) will be able to challenge fecal microbiota, live-jslm in C. difficile treatment.

Children in the LT-001 study treated after onset achieved or maintained additional milestones up to 7.5 years after 1-time intravenous infusion, Novartis says.

Rezafungin (Rezzayo; Cidara Therapeutics Inc, Melinta Therapeutics LLC) is the first new treatment option approved for individuals with candidemia and invasive candidiasis in more than a decade.

As the risk of respiratory depression is elevated with opioid use, the risk of complications from COVID-19 is increased in patients with opioid use disorder.

Among patients with lung cancer, approximately 20% have the earliest stage of disease but are still dying of metastatic lung cancer within about 5 years.

Drugs such as pembrolizumab, sacituzumab govitecan, and datopotamab deruxtecan all have growing bodies of evidence illustrating which patients with cancer are most likely to benefit and in which settings.

Different guidelines have notable differences between equivalency dosing of proton pump inhibitors (PPI), resulting in confusion and a lack of confidence between medical professionals recommending one PPI over another.

Research has even shown that cancer diagnosis can be significantly improved using AI, with real-time data updates, personalized attention, and ultimately better results at lower costs.

The test did not reach the World Health Organization’s minimum performance requirement, which is 80% sensitivity for SARS-CoV-2, in the study population.

Prevention, role of advanced machine learning systems, safety should be top of mind for next 12 months and beyond

Despite tensions that can occur, building relationships with health systems and finding opportunities to collaborate is crucial to improve cancer care.

Children who died from fatal poisoning were often at home and in the presence of an adult.

The treatment shows positive results in metastasis-free survival for men with non-metastatic hormone-sensitive prostate cancer, Pfizer and Astellas announce.

3D biofabrication models reflect increasing global awareness of the ethics of preclinical studies and an increased need for determining therapeutic efficacy differences.

Nick Ferreyros, managing director of policy, advocacy, and communications at the Community Oncology Alliance, discussed the Alliance’s efforts surrounding PBMs and 340B reform.

Retifanlimab-dlwr (Zynyz; Incyte) was granted FDA accelerated approval for metastatic or recurrent locally advanced Merkel cell carcinoma.

There is no single thing that can prevent all cancer risk, but there are 6 pillars of lifestyle that people can adopt to best prevent the disease.

Kandy Dunnigan, AAS, CPhT-Adv, a drug diversion analyst at Novant Health, discusses her role in the pharmacy.

Strong interprofessional team helps ensure safe transitions and minimize adverse events, medication errors

Evinacumab-dgnb (Evkeeza; Regeneron Pharmaceuticals, Inc) is the first FDA-approved treatment indicated for children as young as 5 years of age to treat dangerously high levels of LDL-C.

Blinded arms of the study will continue to evaluate the combination therapy with docetaxel vs docetaxel alone, Merck says.

Sandoz intends to launch the latest Humira biosimilar in the United States on July 1, 2023.

Educating patients, providers improves acceptance, trust as number of approvals, indications grows

The portfolio of oral oncology products has evolved over the past few years and so has the traditional model of distribution.

For the management of ovarian cancer, it has been observed in both cellular and animal models that curcumin suppresses cell proliferation and promotes apoptosis.

The COVID-19 pandemic marginally affected the negative mental health of women more than men, according to a new study.

Investigators estimate that the effectiveness was higher after 1 or 2 booster doses compared with the primary series alone.

Atea’s drug candidate is considered safe and effective against the viruses that cause COVID-19 and hepatitis C, according to new data presented at ICAR 2023.

Therapy effectively treats cells harboring HR deficiencies, including those of specific types of ovarian, breast cancers.